Abstract
Summary
A mental disorder is also called as mental illness or a psychiatric disorder. Mental disorders are generally defined according to how an individual behave, feels, perceives and thinks, and mental disorder occurs due to damage or problems associated with functions of brain. There are various types of mental disorders such as depression, bipolar disorder, schizophrenia and other psychoses, dementia, and developmental disorders including autism.
These disorders can be treated with the help of various medications such as anti-depressants, antianxiety drugs and can also be treated with self-help therapies such as psychotherapy, brain stimulation treatments, and others.
The global market for Mental Disorder Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Mental Disorder Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Mental Disorder Treatment by region & country, by Type, and by Application.
The Mental Disorder Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mental Disorder Treatment.
Market Segmentation
By Company
Allergan Plc
Eli Lilly and Company
VistaGen Therapeutics
Sanofi S.A
Novartis International AG
Mylan N.V
Amneal Pharmaceuticals LLC
Cipla Ltd
Sun Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Limited
Lupin Limited
Janssen Pharmaceutica
Bristol Myers Squibb
Sumitomo Dainippon Pharma Co., Ltd
Segment by Type:
Medications
Self-help Therapies
Segment by Application
Depression
Bipolar Disorder
Schizophrenia
Dementia
Post-traumatic Stress Disorder
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Mental Disorder Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Mental Disorder Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Mental Disorder Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
These disorders can be treated with the help of various medications such as anti-depressants, antianxiety drugs and can also be treated with self-help therapies such as psychotherapy, brain stimulation treatments, and others.
The global market for Mental Disorder Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Mental Disorder Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Mental Disorder Treatment by region & country, by Type, and by Application.
The Mental Disorder Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mental Disorder Treatment.
Market Segmentation
By Company
Allergan Plc
Eli Lilly and Company
VistaGen Therapeutics
Sanofi S.A
Novartis International AG
Mylan N.V
Amneal Pharmaceuticals LLC
Cipla Ltd
Sun Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Limited
Lupin Limited
Janssen Pharmaceutica
Bristol Myers Squibb
Sumitomo Dainippon Pharma Co., Ltd
Segment by Type:
Medications
Self-help Therapies
Segment by Application
Depression
Bipolar Disorder
Schizophrenia
Dementia
Post-traumatic Stress Disorder
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Mental Disorder Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Mental Disorder Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Mental Disorder Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Mental Disorder Treatment Product Introduction
1.2 Global Mental Disorder Treatment Market Size Forecast
1.3 Mental Disorder Treatment Market Trends & Drivers
1.3.1 Mental Disorder Treatment Industry Trends
1.3.2 Mental Disorder Treatment Market Drivers & Opportunity
1.3.3 Mental Disorder Treatment Market Challenges
1.3.4 Mental Disorder Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Mental Disorder Treatment Players Revenue Ranking (2023)
2.2 Global Mental Disorder Treatment Revenue by Company (2019-2024)
2.3 Key Companies Mental Disorder Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Mental Disorder Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Mental Disorder Treatment
2.6 Mental Disorder Treatment Market Competitive Analysis
2.6.1 Mental Disorder Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Mental Disorder Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mental Disorder Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Medications
3.1.2 Self-help Therapies
3.2 Global Mental Disorder Treatment Sales Value by Type
3.2.1 Global Mental Disorder Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Mental Disorder Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Mental Disorder Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Depression
4.1.2 Bipolar Disorder
4.1.3 Schizophrenia
4.1.4 Dementia
4.1.5 Post-traumatic Stress Disorder
4.1.6 Others
4.2 Global Mental Disorder Treatment Sales Value by Application
4.2.1 Global Mental Disorder Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Mental Disorder Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Mental Disorder Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Mental Disorder Treatment Sales Value by Region
5.1.1 Global Mental Disorder Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Mental Disorder Treatment Sales Value by Region (2019-2024)
5.1.3 Global Mental Disorder Treatment Sales Value by Region (2025-2030)
5.1.4 Global Mental Disorder Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Mental Disorder Treatment Sales Value, 2019-2030
5.2.2 North America Mental Disorder Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Mental Disorder Treatment Sales Value, 2019-2030
5.3.2 Europe Mental Disorder Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Mental Disorder Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Mental Disorder Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Mental Disorder Treatment Sales Value, 2019-2030
5.5.2 South America Mental Disorder Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Mental Disorder Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Mental Disorder Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Mental Disorder Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Mental Disorder Treatment Sales Value
6.3 United States
6.3.1 United States Mental Disorder Treatment Sales Value, 2019-2030
6.3.2 United States Mental Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Mental Disorder Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Mental Disorder Treatment Sales Value, 2019-2030
6.4.2 Europe Mental Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Mental Disorder Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Mental Disorder Treatment Sales Value, 2019-2030
6.5.2 China Mental Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Mental Disorder Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Mental Disorder Treatment Sales Value, 2019-2030
6.6.2 Japan Mental Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Mental Disorder Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Mental Disorder Treatment Sales Value, 2019-2030
6.7.2 South Korea Mental Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Mental Disorder Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Mental Disorder Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Mental Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Mental Disorder Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Mental Disorder Treatment Sales Value, 2019-2030
6.9.2 India Mental Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Mental Disorder Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Allergan Plc
7.1.1 Allergan Plc Profile
7.1.2 Allergan Plc Main Business
7.1.3 Allergan Plc Mental Disorder Treatment Products, Services and Solutions
7.1.4 Allergan Plc Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Allergan Plc Recent Developments
7.2 Eli Lilly and Company
7.2.1 Eli Lilly and Company Profile
7.2.2 Eli Lilly and Company Main Business
7.2.3 Eli Lilly and Company Mental Disorder Treatment Products, Services and Solutions
7.2.4 Eli Lilly and Company Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Eli Lilly and Company Recent Developments
7.3 VistaGen Therapeutics
7.3.1 VistaGen Therapeutics Profile
7.3.2 VistaGen Therapeutics Main Business
7.3.3 VistaGen Therapeutics Mental Disorder Treatment Products, Services and Solutions
7.3.4 VistaGen Therapeutics Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Sanofi S.A Recent Developments
7.4 Sanofi S.A
7.4.1 Sanofi S.A Profile
7.4.2 Sanofi S.A Main Business
7.4.3 Sanofi S.A Mental Disorder Treatment Products, Services and Solutions
7.4.4 Sanofi S.A Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Sanofi S.A Recent Developments
7.5 Novartis International AG
7.5.1 Novartis International AG Profile
7.5.2 Novartis International AG Main Business
7.5.3 Novartis International AG Mental Disorder Treatment Products, Services and Solutions
7.5.4 Novartis International AG Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Novartis International AG Recent Developments
7.6 Mylan N.V
7.6.1 Mylan N.V Profile
7.6.2 Mylan N.V Main Business
7.6.3 Mylan N.V Mental Disorder Treatment Products, Services and Solutions
7.6.4 Mylan N.V Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Mylan N.V Recent Developments
7.7 Amneal Pharmaceuticals LLC
7.7.1 Amneal Pharmaceuticals LLC Profile
7.7.2 Amneal Pharmaceuticals LLC Main Business
7.7.3 Amneal Pharmaceuticals LLC Mental Disorder Treatment Products, Services and Solutions
7.7.4 Amneal Pharmaceuticals LLC Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Amneal Pharmaceuticals LLC Recent Developments
7.8 Cipla Ltd
7.8.1 Cipla Ltd Profile
7.8.2 Cipla Ltd Main Business
7.8.3 Cipla Ltd Mental Disorder Treatment Products, Services and Solutions
7.8.4 Cipla Ltd Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Cipla Ltd Recent Developments
7.9 Sun Pharmaceutical Industries Ltd
7.9.1 Sun Pharmaceutical Industries Ltd Profile
7.9.2 Sun Pharmaceutical Industries Ltd Main Business
7.9.3 Sun Pharmaceutical Industries Ltd Mental Disorder Treatment Products, Services and Solutions
7.9.4 Sun Pharmaceutical Industries Ltd Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Sun Pharmaceutical Industries Ltd Recent Developments
7.10 Glenmark Pharmaceuticals Limited
7.10.1 Glenmark Pharmaceuticals Limited Profile
7.10.2 Glenmark Pharmaceuticals Limited Main Business
7.10.3 Glenmark Pharmaceuticals Limited Mental Disorder Treatment Products, Services and Solutions
7.10.4 Glenmark Pharmaceuticals Limited Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Glenmark Pharmaceuticals Limited Recent Developments
7.11 Lupin Limited
7.11.1 Lupin Limited Profile
7.11.2 Lupin Limited Main Business
7.11.3 Lupin Limited Mental Disorder Treatment Products, Services and Solutions
7.11.4 Lupin Limited Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Lupin Limited Recent Developments
7.12 Janssen Pharmaceutica
7.12.1 Janssen Pharmaceutica Profile
7.12.2 Janssen Pharmaceutica Main Business
7.12.3 Janssen Pharmaceutica Mental Disorder Treatment Products, Services and Solutions
7.12.4 Janssen Pharmaceutica Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Janssen Pharmaceutica Recent Developments
7.13 Bristol Myers Squibb
7.13.1 Bristol Myers Squibb Profile
7.13.2 Bristol Myers Squibb Main Business
7.13.3 Bristol Myers Squibb Mental Disorder Treatment Products, Services and Solutions
7.13.4 Bristol Myers Squibb Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 Bristol Myers Squibb Recent Developments
7.14 Sumitomo Dainippon Pharma Co., Ltd
7.14.1 Sumitomo Dainippon Pharma Co., Ltd Profile
7.14.2 Sumitomo Dainippon Pharma Co., Ltd Main Business
7.14.3 Sumitomo Dainippon Pharma Co., Ltd Mental Disorder Treatment Products, Services and Solutions
7.14.4 Sumitomo Dainippon Pharma Co., Ltd Mental Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.14.5 Sumitomo Dainippon Pharma Co., Ltd Recent Developments
8 Industry Chain Analysis
8.1 Mental Disorder Treatment Industrial Chain
8.2 Mental Disorder Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Mental Disorder Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Mental Disorder Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer